Kaláb M, Krechler T
I. interní klinika 1, LF UK a VFN, Praha.
Cas Lek Cesk. 1997 Dec 17;136(24):758-60.
The action of hepatoprotective drugs is a steady subject of discussions. Despite the equivocal character of action hepatoprotective drugs are used, despite the fact that the effect is partly a placebo effect. In the literature are reports on preparation LIV 52 which is a mixture of substances of plant origin and improves the subjective complaints of patients as well as the objective condition of patients with liver disease.
The effect of preparation LIV 52 was investigated in a retrospective study in 19 patients with liver damage. In the majority liver damage caused by alcohol was involved, steatosis and persisting hepatitis without the finding of chronic hepatitis B and C. The authors investigated biochemical parameters (bilirubin, ALT, AST, ALP, TZR, cholesterol). The size of the liver was assessed by ultrasonography and the subjective status of the patients was recorded. Within one year of administration of the preparation subjective improvement occurred, hepatomegaly diminished and the activity of aminotransferases declined.
Administration of LIV 52 can improve the subjective condition and clinical parameters in patients with liver damage, in particular in alcoholic liver damage and in steatosis. The effect is certainly due also to better motivation on the patients part, better lifestyle and dietary measures. After one year of treatment no undesirable side-effects were detected.
保肝药物的作用一直是讨论的热点。尽管其作用存在不确定性，但保肝药物仍被使用，尽管部分效果可能是安慰剂效应。文献中有关于利维 52 制剂的报道，它是一种植物源性物质的混合物，可改善肝病患者的主观症状以及客观状况。
在一项回顾性研究中，对 19 例肝损伤患者使用利维 52 制剂进行了疗效研究。大多数患者的肝损伤由酒精引起，存在脂肪变性和持续性肝炎，但未发现慢性乙型和丙型肝炎。作者研究了生化参数（胆红素、谷丙转氨酶、谷草转氨酶、碱性磷酸酶、总胆汁酸、胆固醇）。通过超声检查评估肝脏大小，并记录患者的主观状况。在使用该制剂的一年内，患者主观症状改善，肝肿大减轻，转氨酶活性下降。
使用利维 52 可改善肝损伤患者的主观状况和临床参数，尤其是酒精性肝损伤和脂肪变性患者。这种效果当然也可能归因于患者更好的积极性、更好的生活方式和饮食措施。治疗一年后未发现不良副作用。
